Insmed reports positive 12-month TPIP extension data in pulmonary arterial hypertension study
INSM•INSM•INSM•INSM•About 65% of patients reached refined low-risk status on REVEAL Lite 2.0 by month 12, and scores improved 2 points or 1.4 points.
The safety profile stayed consistent through month 12 with no new signals; 7.7% discontinued, and four deaths were reported, none treatment-related.
Phase 3 PALM-PAH has started, and its primary endpoint is change in 6-minute walk distance over 24 weeks.
Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting continued late-stage development.
The company said 6-minute walk distance rose about 55 meters from baseline in both the TPIP-continued and placebo-crossed groups, while NT-proBNP fell about 60%.
